Pfizer rescues biotech
The $43bn deal for Seagen marks the biggest biopharma acquisition since the pre-crash takeouts of Allergan and Celgene.
ACC 2023 – Merck’s oral cholesterol lowerer shows mid-stage promise
The oral PCSK9 project MK-0616 meets its targets in phase 2, which could be bad news for Novartis.
ACC 2023 – Merck reaches for the stars
The Stellar trial of sotatercept lives up to its name, but the asset did not come cheap.
Immuno-oncology combinations and beyond
The latest edition of the PD(L)anner focuses on combinations, and analyses the difficulties China developers are having with US approvals.